journal
MENU ▼
Read by QxMD icon Read
search

Oncologist

journal
https://www.readbyqxmd.com/read/29158373/revisiting-expectations-in-an-era-of-precision-oncology
#1
Emily J Marchiano, Andrew C Birkeland, Paul L Swiecicki, Kayte Spector-Bagdady, Andrew G Shuman
As we enter an era of precision medicine and targeted therapies in the treatment of metastatic cancer, we face new challenges for patients and providers alike as we establish clear guidelines, regulations, and strategies for implementation. At the crux of this challenge is the fact that patients with advanced cancer may have disproportionate expectations of personal benefit when participating in clinical trials designed to generate generalizable knowledge. Patient and physician goals of treatment may not align, and reconciliation of their disparate perceptions must be addressed...
November 20, 2017: Oncologist
https://www.readbyqxmd.com/read/29158372/enhancing-next-generation-sequencing-guided-cancer-care-through-cognitive-computing
#2
Nirali M Patel, Vanessa V Michelini, Jeff M Snell, Saianand Balu, Alan P Hoyle, Joel S Parker, Michele C Hayward, David A Eberhard, Ashley H Salazar, Patrick McNeillie, Jia Xu, Claudia S Huettner, Takahiko Koyama, Filippo Utro, Kahn Rhrissorrakrai, Raquel Norel, Erhan Bilal, Ajay Royyuru, Laxmi Parida, H Shelton Earp, Juneko E Grilley-Olson, D Neil Hayes, Stephen J Harvey, Norman E Sharpless, William Y Kim
BACKGROUND: Using next-generation sequencing (NGS) to guide cancer therapy has created challenges in analyzing and reporting large volumes of genomic data to patients and caregivers. Specifically, providing current, accurate information on newly approved therapies and open clinical trials requires considerable manual curation performed mainly by human "molecular tumor boards" (MTBs). The purpose of this study was to determine the utility of cognitive computing as performed by Watson for Genomics (WfG) compared with a human MTB...
November 20, 2017: Oncologist
https://www.readbyqxmd.com/read/29158371/perception-of-curability-among-advanced-cancer-patients-an-international-collaborative-study
#3
Sriram Yennurajalingam, Luis Fernando Rodrigues, Omar Shamieh, Colombe Tricou, Marilène Filbet, Kyaw Naing, Akhileshwaran Ramaswamy, Pedro Emilio Perez-Cruz, Mary Jocelyn S Bautista, Sofia Bunge, Mary Ann Muckaden, Vikash Sewram, Sarah Fakrooden, Antonio Tejedor Noguera, Shobha S Rao, Diane Liu, Minjeong Park, Janet L Williams, Zhanni Lu, Hilda Cantu, David Hui, Suresh K Reddy, Eduardo Bruera
BACKGROUND: There are limited data on illness understanding and perception of cure among advanced cancer patients around the world. The aim of the study was to determine the frequency and factors associated with inaccurate perception of curability among advanced cancer patients receiving palliative care across the globe. MATERIALS AND METHODS: Secondary analysis of a study to understand the core concepts in end-of-life care among advanced cancer patients receiving palliative care from 11 countries across the world...
November 20, 2017: Oncologist
https://www.readbyqxmd.com/read/29158370/ovarian-and-uterine-functions-in-female-survivors-of-childhood-cancers
#4
REVIEW
Ozgur Oktem, Samuel S Kim, Ugur Selek, Glenn Schatmann, Bulent Urman
Adult survivors of childhood cancers are more prone to developing poor reproductive and obstetrical outcomes than their siblings and the general population as a result of previous exposure to chemotherapy and radiation during childhood. Chemotherapy drugs exert cytotoxic effects systemically and therefore can damage the ovaries, leading to infertility, premature ovarian failure, and, to a lesser extent, spontaneous abortions. They have very limited or no deleterious effects on the uterus that can be recognized clinically...
November 20, 2017: Oncologist
https://www.readbyqxmd.com/read/29158369/trailblazing-precision-oncology-for-rare-tumor-subtypes
#5
Kevin Shee, Todd W Miller
No abstract text is available yet for this article.
November 20, 2017: Oncologist
https://www.readbyqxmd.com/read/29158368/anti-hu-associated-autoimmune-limbic-encephalitis-in-a-patient-with-pd-1-inhibitor-responsive-myxoid-chondrosarcoma
#6
Kyriakos P Papadopoulos, Rebecca S Romero, Gabriela Gonzalez, James E Dix, Israel Lowy, Matthew Fury
Autoimmune encephalitis is an uncommon complication of immune checkpoint inhibitor therapy. This article reports a case of fatal anti-Hu-associated autoimmune limbic encephalitis presenting within 8 weeks following anti-PD1 therapy in a patient with myxoid chondrosarcoma and pre-existing anti-Hu antibodies. Although tumor reduction occurred in response to PD-1 inhibitor therapy, the patient had a rapidly progressive decline in neurologic function despite initial stabilization with immunosuppression. Considering the increasing use of immune checkpoint inhibitors for the treatment of various malignancies, an increase in the occurrence of neurologic adverse events is likely, requiring prompt intervention and enhanced pharmacovigilance in malignancies associated with onconeuronal antibodies...
November 20, 2017: Oncologist
https://www.readbyqxmd.com/read/29158367/safety-pharmacokinetics-pharmacodynamics-and-antitumor-activity-of-necuparanib-combined-with-nab-paclitaxel-and-gemcitabine-in-patients-with-metastatic-pancreatic-cancer-phase-i-results
#7
Eileen M O'Reilly, James Roach, Paul Miller, Kenneth H Yu, Catherine Tjan, Molly Rosano, Silva Krause, William Avery, Julie Wolf, Keith Flaherty, Darrell Nix, David P Ryan
LESSONS LEARNED: Despite the compelling preclinical rationale of evaluating the genetically engineered heparin derivative, necuparanib, combined with standard therapy in metastatic pancreas adenocarcinoma, the results were ultimately disappointing.Safety was documented, although dose escalation was limited by the number of subcutaneous injections, the potential for skin toxicity (cellulitis), and low-level anticoagulant effect. Nonetheless, the hypothesis of targeting prothrombotic pathways in pancreas adenocarcinoma remains compelling...
November 20, 2017: Oncologist
https://www.readbyqxmd.com/read/29158366/therapeutic-anticoagulation-in-patients-with-primary-brain-tumors-or-secondary-brain-metastasis
#8
REVIEW
Richard J Lin, David L Green, Gunjan L Shah
Patients with primary or metastatic brain tumors are at increased risk of developing venous thromboses. However, the potential benefit of therapeutic anticoagulation in these patients must be weighed against the deadly complication of intracranial hemorrhage. In this review, we summarize available evidence and recent studies of intracranial bleeding risks in primary and metastatic tumors and the impact of therapeutic anticoagulation. We find that for the majority of primary and treated metastatic brain tumors, the risk of spontaneous bleeding is acceptable and not further increased by careful therapeutic anticoagulation with low molecular weight heparin or direct oral anticoagulants, although thrombocytopenia (platelet count less than 50,000/μL) and other coagulopathies are relative contraindications...
November 20, 2017: Oncologist
https://www.readbyqxmd.com/read/29158365/phase-ii-trial-using-a-combination-of-oxaliplatin-capecitabine-and-celecoxib-with-concurrent-radiation-for-newly-diagnosed-resectable-rectal-cancer
#9
Emilio P Araujo-Mino, Yehuda Z Patt, Cristina Murray-Krezan, Joshua A Hanson, Pranshu Bansal, Ben J Liem, Ashwani Rajput, M Houman Fekrazad, Glenory Heywood, Fa Chyi Lee
LESSONS LEARNED: Colorectal cancers exhibit a high level of cyclooxygenase-2 (COX-2) expression with strong preclinical rationale for improved clinical outcomes with COX-2 inhibition. Celecoxib is a COX-2 inhibitor and we have shown that it can be safely combined with capecitabine and oxaliplatin as part of neoadjuvant treatment with radiation therapy (RT) in rectal cancer.There was a significant improvement in skin toxicity with this combination as compared with historical data. Considering the field has moved on to single-agent capecitabine, we believe future trials with capecitabine and celecoxib hold potential...
November 20, 2017: Oncologist
https://www.readbyqxmd.com/read/29158364/adverse-event-reporting-in-clinical-trials-time-to-include-duration-as-well-as-severity
#10
EDITORIAL
Oliver Sartor
No abstract text is available yet for this article.
November 20, 2017: Oncologist
https://www.readbyqxmd.com/read/29158363/phase-i-pharmacokinetic-study-of-nivolumab-in-korean-patients-with-advanced-solid-tumors
#11
Keun-Wook Lee, Dae Ho Lee, Jin Hyoung Kang, Joon Oh Park, Se Hyun Kim, Yong Sang Hong, Seung Tae Kim, Do-Youn Oh, Yung-Jue Bang
LESSONS LEARNED: This pharmacokinetic study of nivolumab showed that there is little ethnic difference in the handling of nivolumab.Nivolumab was well tolerated in Korean patients. BACKGROUND: This phase I study of nivolumab, an anti-programmed cell death-1 (anti-PD-1) monoclonal antibody, investigated the pharmacokinetics and safety of nivolumab in Korean patients with advanced solid tumors. Findings were compared with results from Japan and the U.S. MATERIALS AND METHODS: In this two-part study, patients received a single dose of nivolumab (1, 3, and 10 mg/kg; ONO-4538-13) and were followed up for 3 weeks...
November 20, 2017: Oncologist
https://www.readbyqxmd.com/read/29146618/management-of-adverse-events-associated-with-cabozantinib-therapy-in-renal-cell-carcinoma
#12
REVIEW
Manuela Schmidinger, Romano Danesi
Cabozantinib was recently approved for the treatment of advanced renal cell carcinoma (RCC) after treatment with vascular endothelial growth factor (VEGF)-targeted therapy. Cabozantinib is a multikinase inhibitor targeting VEGF receptor (VEGFR) 2, mesenchymal-epithelial transition receptor, and "anexelekto" receptor tyrosine kinase. A 60-mg daily dose led to improved overall survival and progression-free survival (PFS) versus everolimus in advanced RCC patients as a second- or later-line treatment in the METEOR trial...
November 16, 2017: Oncologist
https://www.readbyqxmd.com/read/29146617/cure-in-advanced-renal-cell-cancer-is-it-an-achievable-goal
#13
Dhanusha Sabanathan, John J Park, Manuel Marquez, Louise Francisco, Natalie Byrne, Howard Gurney
BACKGROUND: Immunotherapy has historically been of interest in the management of metastatic renal cell cancer (mRCC) because of its relative chemoresistance and the reproducible but low incidence of spontaneous remission in metastatic disease. Recently, targeted immunotherapies in the form of checkpoint inhibitors have shown durable responses in approximately 20%-30% of patients with solid tumors, with a much more acceptable side-effect profile. Anti-programmed death receptor 1 (PD-1)/programmed death receptor ligand 1 antibodies rely on the presence of host T cells in the tumor microenvironment to be stimulated in order to activate an antitumor response...
November 16, 2017: Oncologist
https://www.readbyqxmd.com/read/29146616/therapeutic-potential-of-afatinib-for-cancers-with-erbb2-her2-transmembrane-domain-mutations-g660d-and-v659e
#14
Hiromasa Yamamoto, Shinichi Toyooka, Takashi Ninomiya, Shigemi Matsumoto, Masashi Kanai, Shuta Tomida, Katsuyuki Kiura, Manabu Muto, Ken Suzawa, Patrice Desmeules, Mark G Kris, Bob T Li, Marc Ladanyi
We previously reported on a family with hereditary lung cancer, in which a germline mutation in the transmembrane domain (G660D) of avian erythroblastic leukemia viral oncogene homolog 2 (erb-b2 receptor tyrosine kinase 2) (ERBB2; human epidermal growth factor receptor 2 [HER2]) seemed to be responsible for the cancer predisposition. Although few data are available on treatment, anti-ERBB2 therapeutic agents may be effective for ERBB2-mutant cancers. The familial lung cancer patient in one of the authors' institutes developed bone metastasis with enlarging lung tumors and was treated with the ERBB2 inhibitor afatinib...
November 16, 2017: Oncologist
https://www.readbyqxmd.com/read/29133518/in-reply
#15
LETTER
Richard M Goldberg, Lai Wei, Soledad Fernandez
No abstract text is available yet for this article.
November 13, 2017: Oncologist
https://www.readbyqxmd.com/read/29133517/clinical-trials-in-oncology-and-defining-benefit
#16
LETTER
Steven Sorscher
No abstract text is available yet for this article.
November 13, 2017: Oncologist
https://www.readbyqxmd.com/read/29133516/quality-of-randomized-controlled-trials-reporting-in-the-treatment-of-adult-patients-with-high-grade-gliomas
#17
Magalie P Tardy, Jocelyn Gal, Emmanuel Chamorey, Fabien Almairac, Fanny Vandenbos, Pierre-Yves Bondiau, Esma Saada-Bouzid
BACKGROUND: The randomized controlled trial (RCT) is the gold standard to objectively assess the effect of treatments. To help improve the quality of RCTs, experts established a list of recommendations, the CONsolidated Standards of Reporting Trials (CONSORT) Statement. In this study, we evaluated the implementation of the CONSORT Statement in the field of high-grade gliomas in adult patients and looked for criteria associated with higher quality of RCTs. MATERIALS AND METHODS: We searched all high-grade gliomas RCTs published in PubMed between January 1990 and December 2016...
November 13, 2017: Oncologist
https://www.readbyqxmd.com/read/29133515/-rather-one-more-chemo-than-one-less%C3%A2-oncologists-and-oncology-nurses-reasons-for-aggressive-treatment-of-young-adults-with-advanced-cancer
#18
Katsiaryna Laryionava, Pia Heußner, Wolfgang Hiddemann, Eva C Winkler
BACKGROUND: Empirical research demonstrates that there is a tendency to administer tumor-directed therapy to patients with advanced cancer close to death, especially if they are young. The aim of this qualitative study was to understand oncologists' treatment decisions and oncology nurses' perception of these decisions in young adult patients and to investigate the extent to which young age was a factor in cancer treatment decisions. MATERIALS AND METHODS: We conducted 29 face-to-face interviews with oncologists and oncology nurses at the Department of Hematology and Oncology at the University Hospital in Munich, Germany...
November 13, 2017: Oncologist
https://www.readbyqxmd.com/read/29133514/first-prospective-multicenter-italian-study-on-the-impact-of-the-21-gene-recurrence-score-in-adjuvant-clinical-decisions-for-patients-with-er-positive-her2-negative-breast-cancer
#19
Maria Vittoria Dieci, Valentina Guarneri, Tommaso Giarratano, Marta Mion, Giampaolo Tortora, Costanza De Rossi, Stefania Gori, Cristina Oliani, Laura Merlini, Felice Pasini, Giorgio Bonciarelli, Gaia Griguolo, Enrico Orvieto, Silvia Michieletto, Tania Saibene, Paola Del Bianco, Gian Luca De Salvo, PierFranco Conte
BACKGROUND: The Breast DX Italy prospective study evaluated the impact of the 21-gene recurrence score (RS) result on adjuvant treatment decisions for patients with early breast cancer. MATERIALS AND METHODS: Nine centers (two Hub and seven Spoke centers of the Veneto Oncology Network) participated. Consecutive patients with estrogen receptor positive, human epidermal growth receptor negative, T1-T3, N0-N1 early breast cancer were prospectively registered; only those meeting protocol-defined clinicopathological "intermediate risk" criteria were eligible for the RS test...
November 13, 2017: Oncologist
https://www.readbyqxmd.com/read/29133513/phase-ii-study-of-bevacizumab-and-vorinostat-for-patients-with-recurrent-world-health-organization-grade-4-malignant-glioma
#20
Ashley Ghiaseddin, David Reardon, Woody Massey, Alex Mannerino, Eric S Lipp, James E Herndon, Frances McSherry, Annick Desjardins, Dina Randazzo, Henry S Friedman, Katherine B Peters
LESSONS LEARNED: Combination regimen with bevacizumab (BEV) and vorinostat is well tolerated in patients with recurrent glioblastoma.Treatment of recurrent glioblastoma remains challenging as this study and others attempt to improve progression-free survival and overall survival with BEV-containing regimens. BACKGROUND: Recurrent glioblastoma (GBM; World Health Organization grade 4) continues to have a very poor prognosis. Bevacizumab (BEV) has been shown to improve progression-free survival (PFS) in recurrent GBM and is approved by the U...
November 13, 2017: Oncologist
journal
journal
20207
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"